PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation

Biochemical Pharmacology

Volumn 85, Issue 11, 2013, Pages 1684-1699

  Caruso, Antonello ^a   Alvarez Sánchez, Ruben ^a   Hillebrecht, Alexander ^a   Poirier, Agnès ^a   Schuler, Franz ^a   Lavé, Thierry ^a   Funk, Christoph ^a   Belli, Sara ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cerebrospinal fluid; In vitro in vivo correlations; P glycoprotein substrates; PK PD assessment; Unbound brain concentration

Indexed keywords

BUSPIRONE; DIAZEPAM; DIGOXIN; ELACRIDAR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; PHENYTOIN; QUINIDINE; RISPERIDONE; ZOLPIDEM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PROTEINS; CENTRAL NERVOUS SYSTEM AGENTS; CLUSTER ANALYSIS; DRUG DISCOVERY; LLC-PK1 CELLS; MICE; MODELS, THEORETICAL; P-GLYCOPROTEIN; RATS; SWINE;

EID: 84877635707     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.021     Document Type: Article

References (51)

1. C.M. Mendel The free hormone hypothesis: a physiologically based mathematical model Endocr Rev 10 3 1989 232 274
2. D.A. Smith, L. Di, and E.H. Kerns The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat Rev Drug Discov 9 12 2010 929 939
3. D.D. Shen, A.A. Artru, and K.K. Adkison Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics Adv Drug Deliv Rev 56 12 2004 1825 1857
4. H.S.M.B. Davson Special aspects of the blood-brain barrier in: physiology of the CSF and blood-brain barrier 1996 CRC Press Boca Raton
5. A.A. Artru Cerebrospinal fluid J.E. Cottrell, D.S. Smith, Anaesthesia and neurosurgery 1994 CV Mosby St. Louis 93 116
6. G.A.A.R. Schreiber Molecular cloning of choroidspecific transport proteins W.M. Pardridges, The blood-brain barrier; cellular and molecular biology 1993 Raven Press New York
7. Y. Deguchi, K. Inabe, K. Tomiyasu, K. Nozawa, S. Yamada, and R. Kimura Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis Pharm Res 12 12 1995 1838 1844
8. X. Liu, B.J. Smith, C. Chen, E. Callegari, S.L. Becker, and X. Chen Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration Drug Metab Dispos 34 9 2006 1443 1447
9. J.H. Lin CSF as a surrogate for assessing CNS exposure: an industrial perspective Curr Drug Metab 9 1 2008 46 59
10. G. Xiao, C. Black, G. Hetu, E. Sands, J. Wang, and R. Caputo Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates Drug Metab Dispos 40 4 2012 779 787
11. Y. Deguchi, K. Nozawa, S. Yamada, Y. Yokoyama, and R. Kimura Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system J Pharmacol Exp Ther 280 2 1997 551 560
12. E.C. de Lange, and M. Danhof Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain Clin Pharmacokinet 41 10 2002 691 703
13. J. Westerhout, B. Ploeger, J. Smeets, M. Danhof, and E.C. de Lange Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats Aaps J 14 3 2012 543 553
14. T. Ohe, M. Sato, S. Tanaka, N. Fujino, M. Hata, and Y. Shibata Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio Drug Metab Dispos 31 10 2003 1251 1254
15. H. He, K.A. Lyons, X. Shen, Z. Yao, K. Bleasby, and G. Chan Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure Xenobiotica 39 9 2009 687 693
16. C. Tang, Y. Kuo, N.T. Pudvah, J.D. Ellis, M.S. Michener, and M. Egbertson Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys Biochem Pharmacol 78 6 2009 642 647
17. H. Kodaira, H. Kusuhara, T. Fujita, J. Ushiki, E. Fuse, and Y. Sugiyama Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate J Pharmacol Exp Ther 339 3 2011 935 944
18. Y. Adachi, H. Suzuki, and Y. Sugiyama Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein Pharm Res 18 12 2001 1660 1668
19. J.C. Kalvass, and G.M. Pollack Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition Pharm Res 24 2 2007 265 276
20. D. Schwab, H. Fischer, A. Tabatabaei, S. Poli, and J. Huwyler Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery J Med Chem 46 9 2003 1716 1725
21. D. Weininger Smiles, a chemical language and information-system. 1. Introduction to methodology and encoding rules J Chem Inf Comput Sci 28 1 1988 31 36
22. J. Sadowski, and J. Gasteiger From atoms and bonds to 3-dimensional atomic coordinates-automatic model builders Chem Rev 93 7 1993 2567 2581
23. M. Stahl, H. Mauser, M. Tsui, and N.R. Taylor A robust clustering method for chemical structures J Med Chem 48 13 2005 4358 4366
24. E. Kuhn, and M. Lavielle Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 4 2005 1020 1038
25. P.L. Bonate The art of modeling, in pharmacokinetic-pharmacodynamic modeling and simulation 2011 Springer p. 1-56
26. G. Schwarz Estimating dimension of a model Ann Stat 6 2 1978 461 464
27. H. Akaike A new look at the statistical model identification IEEE Trans Autom Control 19 6 1974 716 723
28. M. Kansy, F. Senner, and K. Gubernator Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J Med Chem 41 7 1998 1007 1010
29. Witten, IH, Frank E. Data mining: practical machine learning tools and techniques. second edition. Morgan Kaufmann: Morgan Kaufmann Series in Data Management Systems; 2005.
30. M.S. Alavijeh, and A.M. Palmer Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds Neurobiol Dis 37 1 2010 38 47
31. A.C. Doran, S.M. Osgood, J.Y. Mancuso, and C.L. Shaffer An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations Drug Metab Dispos 40 11 2012 2162 2173
32. R. Clinckers, I. Smolders, K. Vermoesen, Y. Michotte, M. Danhof, and R. Voskuyl Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations Expert Opin Drug Metab Toxicol 5 10 2009 1267 1277
33. J. Westerhout, M. Danhof, and E.C. De Lange Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting J Pharm Sci 100 9 2011 3577 3593
34. M. Friden, S. Winiwarter, G. Jerndal, O. Bengtsson, H. Wan, and U. Bredberg Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J Med Chem 52 20 2009 6233 6243
35. A. Golbraikh, and A. Tropsha Beware of q2! J Mol Graph Model 20 4 2002 269 276
36. A.H. Schinkel P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Deliv Rev 36 2-3 1999 179 194
37. M.S. Warren, N. Zerangue, K. Woodford, L.M. Roberts, E.H. Tate, and B. Feng Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human Pharmacol Res 59 6 2009 404 413
38. C. Bundgaard, C.J. Jensen, and M. Garmer Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice Drug Metab Dispos 40 3 2012 461 466
39. T. Takeuchi, S. Yoshitomi, T. Higuchi, K. Ikemoto, S. Niwa, and T. Ebihara Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1 Pharm Res 23 7 2006 1460 1472
40. W. Loscher, and H. Potschka Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2 1 2005 86 98
41. J. Kamiie, S. Ohtsuki, R. Iwase, K. Ohmine, Y. Katsukura, and K. Yanai Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria Pharm Res 25 6 2008 1469 1483
42. Y. Uchida, S. Ohtsuki, Y. Katsukura, C. Ikeda, T. Suzuki, and J. Kamiie Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J Neurochem 117 2 2011 333 345
43. V.V. Rao, J.L. Dahlheimer, M.E. Bardgett, A.Z. Snyder, R.A. Finch, and A.C. Sartorelli Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal- fluid drug-permeability barrier Proc Natl Acad Sci USA 96 7 1999 3900 3905
44. Z. Redzic Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences Fluids Barriers CNS 8 1 2011 p3
45. L.M. Roberts, D.S. Black, C. Raman, K. Woodford, M. Zhou, and J.E. Haggerty Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation Neuroscience 155 2 2008 423 438
46. S. Gazzin, N. Strazielle, C. Schmitt, M. Fevre-Montange, J.D. Ostrow, and C. Tiribelli Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces J Comp Neurol 510 5 2008 497 507
47. S. Gazzin, A.L. Berengeno, N. Strazielle, F. Fazzari, A. Raseni, and J.D. Ostrow Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat PLoS ONE 6 1 2011 pe16165
48. S.V. Ambudkar, I.W. Kim, and Z.E. Sauna The power of the pump: mechanisms of action of P-glycoprotein (ABCB1) Eur J Pharm Sci 27 5 2006 392 400
49. Y. Uchida, S. Ohtsuki, J. Kamiie, and T. Terasaki Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice J Pharmacol Exp Ther 339 2 2011 579 588
50. T. Fawcett ROC graphs: notes and practical considerations for researchers, HP laboratories 2004 Kluwer Academic Publishers Palo Alto, CA
51. Tuma, R. The cerebral microcirculation. In Handbook of Physiology, The Cardiovascular System, Microcirculation2008. p. 488, Figure 11.2 [Chapter 11].